Background/aim: The importance of compliance with National Comprehensive Cancer Network (NCCN) guidelines for preventing varicella-zoster virus reactivation (VZVr) in multiple myeloma (MM) in a clinical setting has not been well investigated.
Patients And Methods: We retrospectively studied the clinical characteristics and outcomes of 118 patients with MM treated with proteasome inhibitors.
Results: Thirty-nine episodes of VZVr were observed in 37 patients (VZVr group).